

ROCKWELL MEDICAL, INC.  
Form 8-K  
May 10, 2018

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**Form 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): May 10, 2018

**Rockwell Medical, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Michigan**

(State or Other Jurisdiction of  
Incorporation)

**000-23661**

(Commission File Number)

**38-3317208**

(I.R.S. Employer Identification  
Number)

**30142 Wixom Road, Wixom, Michigan 48393**

(Address of Principal Executive Offices) (Zip Code)

**(248) 960-9009**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ROCKWELL MEDICAL, INC. - Form 8-K

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

---

**Item 2.02. Results of Operations and Financial Condition.**

On May 10, 2018, the Company issued the press release attached hereto as Exhibit 99.1, announcing its financial results for the quarter ended March 31, 2018.

**Item 9.01. Financial Statements and Exhibits.**

The following exhibit is furnished with this Form 8-K:

<u>Exhibit</u>	<u>Description</u>
----------------	--------------------

<u>99.1</u>	<u>Press Release dated May 10, 2018.</u>
-------------	--

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Rockwell Medical, Inc.**

Date: May 10, 2018

By: /s/ Thomas E. Klema  
Thomas E. Klema  
Its: Chief Financial Officer

---

EXHIBIT INDEX

Exhibit   Description

99.1   Press Release dated May 10, 2018.